Elektrostimulation im Ganglion Gasseri (TGES) als Therapieoption bei Trigeminusneuropathie nach (iatrogener) Läsion des Nervus Trigeminus

2005 ◽  
Vol 84 (01) ◽  
Author(s):  
J Mehrkens ◽  
A Leunig ◽  
G Rasp ◽  
U Steude
BMC Neurology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Naureen Keric ◽  
Darius Kalasauskas ◽  
Sophia L. Kreth ◽  
Martin B. Glaser ◽  
Harald Krenzlin ◽  
...  

Abstract Background Trigeminal neuralgia (TN) is a severe pain condition and the most common facial neuralgia. While microvascular decompression (MVD) presents an excellent treatment in neurovascular compression cases, percutaneous thermocoagulation (PT) of the ganglion Gasseri is an alternative option. This study aimed to evaluate post-operative complication rate and outcome of both treatment strategies related to the patient’s age. Methods The medical records of all patients with the diagnosis of trigeminal neuralgia undergoing an MVD or PT of the ganglion Gasseri (between January 2007 and September 2017) were reviewed to determine the efficacy and the complication rate of both methods in regard to the patient’s age. Results Seventy-nine patients underwent MVD surgery and 39 a PT. The mean age of patients in the MVD group was 61 years and 73 years in the PT group. There were 59 (50%) female patients. Nerve-vessel conflict could be identified in 78 (98.7%) MVD and 17 (43.6%) PT patients on preoperative MRI. Charlson comorbidity index was significantly higher in PT group (2.4 (1.8) versus 3.8 (1.8) p < 0.001). The Barrow pain score (BPS) at the last follow-up demonstrated higher scores after PT (p = 0.007). The complication rate was markedly higher in PT group, mostly due to the facial hypesthesia (84.6% versus 27.8%; p < 0.001). Mean symptom-free survival was significantly shorter in the PT group (9 vs. 26 months, p < 0.001). It remained statistically significant when stratified into age groups: (65 years and older: 9 vs. 18 months, p = 0.001). Duration of symptoms (OR 1.005, 95% CI 1.000–1.010), primary procedure (OR 6.198, 95% CI 2.650–14.496), patient age (OR 1.033, 95% CI 1.002–1.066), and postoperative complication rate (OR 2.777, 95% CI 1.309–5.890) were associated with treatment failure. Conclusion In this patient series, the MVD is confirmed to be an excellent treatment option independent of patient’s age. However, while PT is an effective procedure, time to pain recurrence is shorter, and the favorable outcome (BPS 1 and 2) rate is lower compared to MVD. Hence MVD should be the preferred treatment and PT should remain an alternative in very selected cases when latter is not possible but not in the elderly patient per se.


Praxis ◽  
2022 ◽  
Vol 110 (1) ◽  
pp. 21-25
Author(s):  
Katharina Kneppe ◽  
David Czell

Zusammenfassung. Bei der Trigeminusneuralgie kommt es zu kurzen neuropathischen Schmerzen im Versorgungsgebiet des Nervus trigeminus. Unterschieden werden eine klassische, eine symptomatische, und eine idiopathische Trigeminusneuralgie. Für die Akutbehandlung gibt es nur wenige Medikamente. In der vorgestellten Fallserie berichten wir von fünf Personen mit einer Trigeminusneuralgie unterschiedlicher Genese, die gut auf die Behandlung mit Brivaracetam ansprachen. Brivaracetam bindet an das synaptische Vesikelprotein 2A, das auch an Nerven und Nervenwurzeln vorkommt. SV2 reguliert die exozytotische Freisetzung von Neurotransmittern, was die Wirkung von Brivaracetam auf neuropathische Schmerzen erklären könnte. Der Einsatz von Brivaracetam kann bei der kurzfristigen Therapie von paroxysmalen Schmerzen im Rahmen der Trigeminusneuralgie hilfreich sein. Es sind weitere Studien erforderlich, um diese Wirkung nachzuweisen und einen Placeboeffekt auszuschliessen.


Sign in / Sign up

Export Citation Format

Share Document